Article Versions Notes

McAllister M, Flanagan T, Boon K, Pepin X, Tistaert C, Jamei M, Abend A, Kotzagiorgis E, Mackie C. Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives. Pharmaceutics. 2020; 12(1):19. https://doi.org/10.3390/pharmaceutics12010019

McAllister, Mark, Talia Flanagan, Karin Boon, Xavier Pepin, Christophe Tistaert, Masoud Jamei, Andreas Abend, Evangelos Kotzagiorgis, and Claire Mackie. 2020. "Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives" Pharmaceutics 12, no. 1: 19. https://doi.org/10.3390/pharmaceutics12010019

McAllister, M., Flanagan, T., Boon, K., Pepin, X., Tistaert, C., Jamei, M., Abend, A., Kotzagiorgis, E., & Mackie, C. (2020). Developing Clinically Relevant Dissolution Specifications for Oral Drug Products—Industrial and Regulatory Perspectives. Pharmaceutics, 12(1), 19. https://doi.org/10.3390/pharmaceutics12010019